{"organizations": [], "uuid": "eba2a8622d958f5ff986ea99f579bac69956055f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180208.html", "section_title": "Archive News &amp; Video for Thursday, 08 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-johnson-johnson-says-zytiga-approv/brief-johnson-johnson-says-zytiga-approved-for-treatment-of-prostate-cancer-idUSFWN1PY127", "country": "US", "domain_rank": 408, "title": "BRIEF-Johnson & Johnson says ZYTIGA Approved For Treatment Of Prostate Cancer", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.927, "site_type": "news", "published": "2018-02-08T21:29:00.000+02:00", "replies_count": 0, "uuid": "eba2a8622d958f5ff986ea99f579bac69956055f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-johnson-johnson-says-zytiga-approv/brief-johnson-johnson-says-zytiga-approved-for-treatment-of-prostate-cancer-idUSFWN1PY127", "ord_in_thread": 0, "title": "BRIEF-Johnson & Johnson says ZYTIGA Approved For Treatment Of Prostate Cancer", "locations": [], "entities": {"persons": [{"name": "johnson", "sentiment": "negative"}, {"name": "janssen", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters) - johnson & johnson", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 8 (Reuters) - Johnson & Johnson:\n* ZYTIGAÂ® (ABIRATERONE ACETATE) PLUS PREDNISONE APPROVED FOR TREATMENT OF EARLIER FORM OF METASTATIC PROSTATE CANCER\n* JANSSEN - PHASE 3 LATITUDE CLINICAL TRIAL DATA DEMONSTRATED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENTS IN PATIENTS Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-08T21:29:00.000+02:00", "crawled": "2018-02-09T16:29:28.004+02:00", "highlightTitle": ""}